Emergent Biosolutions
EBS
156 hedge funds and large institutions have $332M invested in Emergent Biosolutions in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 21 closing their positions.
116% more call options, than puts
Call options by funds: $4.86M | Put options by funds: $2.25M
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
26% more capital invested
Capital invested by funds: $265M → $332M (+$67.5M)
11% more funds holding
Funds holding: 140 → 156 (+16)
5.45% more ownership
Funds ownership: 58.66% → 64.1% (+5.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.17M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$5.86M |
| 3 |
Goldman Sachs
New York
|
+$4.78M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.38M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$10.7M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$8.58M |
| 3 |
D.E. Shaw & Co
New York
|
-$3.56M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.81M |
| 5 |
KLP
Kent Lake PR
Anasco,
Puerto Rico
|
-$1.67M |
EBS Hedge Fund Activity: Q4 2024 in Review
156 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2024, worth a combined $332M — up 26% from $265M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new EBS positions and 21 closed out — a net gain of 16 holders — while 46 added to existing stakes and 36 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.17M. The largest seller was Marshall Wace, cutting an estimated $10.7M.
- 156 institutional investors held Emergent Biosolutions (EBS) as of Q4 2024, up from 140 in Q3 2024.
- Funds reported $332M of Emergent Biosolutions stock for Q4 2024, up 26% quarter-over-quarter.
- 37 funds opened new Emergent Biosolutions positions in Q4 2024 and 21 closed out, a net change of +16 holders.
- The largest Emergent Biosolutions buyer in Q4 2024 was Millennium Management, an estimated $6.17M added.
- The largest Emergent Biosolutions seller in Q4 2024 was Marshall Wace, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2024.